Phosphagenics appoints pharma veteran

By Dylan Bushell-Embling
Tuesday, 08 July, 2008

Phosphagenics [ASX: POH] has appointed Michael Ashton to its board as a non-executive director.

Ashton will also act as a consultant on the Melbourne's company's commercialisation strategies.

Ashton has worked for over three decades in the international pharmaceutical industry, including having held senior management positions at Merck, Pfizer and Faulding.

Ashton also served as CEO for SkyePharma PLC.

Farm animals and aquaculture cryopreservation partnership announced

Vitrafy Life Sciences Limited has announced that it has entered a 12-month exclusive agreement...

Babies of stressed mothers likely to get their teeth earlier

Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...

Customised immune cells used to fight brain cancer

Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...

Content from other channels on our network

Siemens introduces industrial metaverse design environment

IFR predicts the top five global robotics trends for 2026

UNSW researchers find uses for textiles and other wastes

Queensland BESS project gets grid connection approval

Local defence manufacturing receives funding boost

Carbon-conversion technology creates chemicals for jet fuel

Novel energy storage system to decarbonise buildings

F-Gas Regulation: Turning necessity into opportunity

Tiny gold spheres could improve solar energy harvesting

Methane reduction trial uses nature-based supplement

Afnor acquires HACCP Australia and HACCP International

Solving the limitations for paper packaging with coating strategy

Packserv expands into the US with its packaging machinery

Keeping PEZ tablets rolling consistently with print upgrade

Food-grade upscaling line for 'new food' developments